DSC
VRTX icon

Duncker Streett & Co’s Vertex Pharmaceuticals VRTX Stock Holding History

Duncker Streett & Co’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$765K Sell
1,541
-550
-26% -$244K 0.13% 131
2026
Q1 		$934K Sell
2,091
-20
-0.9% -$9.33K 0.18% 105
2025
Q4 		$957K Sell
2,111
-244
-10% -$105K 0.17% 103
2025
Q3 		$922K Sell
2,355
-5,377
-70% -$2.25M 0.16% 102
2025
Q2 		$3.44M Sell
7,732
-15
-0.2% -$6.91K 0.63% 39
2025
Q1 		$3.76M Buy
7,747
+84
+1% +$39.1K 0.74% 35
2024
Q4 		$3.09M Buy
7,663
+335
+5% +$155K 0.57% 49
2024
Q3 		$3.41M Buy
7,328
+903
+14% +$434K 0.62% 46
2024
Q2 		$3.01M Buy
+6,425
New +$2.79M 0.58% 52
2020
Q4 		– Sell
-200
Closed -$54K – 563
2020
Q3 		$54K Buy
200
+50
+33% +$13.8K 0.01% 317
2020
Q2 		$44K Buy
+150
New +$40.7K 0.01% 330
2019
Q2 		– Sell
-300
Closed -$55K – 579
2019
Q1 		$55K Buy
+300
New +$55.4K 0.01% 365

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Duncker Streett & Co's VRTX Position: Q2 2026 in Review

Duncker Streett & Co reduced its Vertex Pharmaceuticals (VRTX) stake by 26% in Q2 2026, selling an estimated $244K and leaving 1,541 shares worth $765K. The position accounts for 0.13% of the portfolio, ranked #131.

Duncker Streett & Co first reported a position in VRTX in Q1 2019 and has held it in 12 quarters since. The position peaked at $3.76M in Q1 2025. 1,757 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Duncker Streett & Co held 1,541 shares of Vertex Pharmaceuticals worth $765K as of Q2 2026.
  • Duncker Streett & Co sold 550 Vertex Pharmaceuticals shares in Q2 2026, an estimated $244K.
  • Vertex Pharmaceuticals made up 0.13% of Duncker Streett & Co's portfolio in Q2 2026, its #131 holding.
  • Duncker Streett & Co first reported a position in Vertex Pharmaceuticals in Q1 2019 and has held it in 12 quarters since.
  • Duncker Streett & Co's Vertex Pharmaceuticals position peaked at $3.76M in Q1 2025.
  • 1,757 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Duncker Streett & Co's 13F filing for Q2 2026, filed 28 Jul 2026.